Ratings Mabion S.A.

Equities

MAB

PLMBION00016

Market Closed - Warsaw S.E. Other stock markets 11:55:56 2024-05-02 am EDT			5-day change	1st Jan Change
16.52 ^PLN	+1.47%		+0.12%	-8.98%

Apr. 16	Mabion S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Mabion S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
The opinion of analysts covering the stock has improved over the past four months.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Most analysts recommend that the stock should be sold or reduced.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MABION S.A.	-8.98%	66.45M	-
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B	B+
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B	B+
ARGENX SE	+4.40%	22.94B	B
BIONTECH SE	-12.15%	22.34B	B+
GENMAB A/S	-4.36%	19.25B	A-
WUXI APPTEC CO., LTD.	-39.98%	17.08B	A-
BEIGENE, LTD.	-10.04%	16.96B	B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.16B	C+
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes